文献速递慢性肾脏病血液净化与透析

英国扩大SGLT-2抑制剂适应症对CKD的模型获益

Modelled CKD Benefits of Broad Sodium-Glucose Cotransporter-2 Inhibitor Eligibility in the UK.
PubMed 文献 · Kidney Int Rep · 2026-05-15

本研究使用经验证的IMPACT CKD个体水平微模拟模型,模拟2025年起10年内5种SGLT-2抑制剂(SGLT-2i)CKD准入场景。与最大范围纳入场景相比,准入越严格,透析与全因死亡增加越多,非肾脏替代治疗(KRT)CKD费用与KRT费用上升,但总费用因治疗人数减少而下降,KRT相关环境负担上升。

要点

  • 扩大SGLT-2i准入可能同时降低患者、NHS与环境的CKD整体负担
  • 准入越严格,透析与全因死亡、KRT费用及环境负担越高
  • 限制准入虽降低总费用,但以更差临床结局为代价

核心结论

  • 广泛SGLT-2i准入标准很可能降低CKD对患者、英国国家医疗服务体系(NHS)和环境的整体负担。

研究设计与样本

  • 采用经验证的IMPACT CKD个体水平微模拟模型,从2025年起对CKD患者模拟10年,探索5种SGLT-2i准入标准场景,经济结局按每年3.5%贴现。

主要发现

  • 与最大范围纳入场景相比,准入越严格,透析和全因死亡率分别增加4.0%至17.2%和1.3%至4.3%。
  • 因死亡率升高,CKD患病率预计降低0.5%至1.4%。
  • 非KRT的CKD费用和KRT费用分别增加0.7%至2.1%和2.4%至10.6%。
  • 总费用降低15.2%至33.9%,因接受治疗的患者减少。
  • 因疾病向更晚期阶段转移,KRT相关环境负担增加3.1%至14.9%。

临床怎么用

  • 提示肾内科智能体在评估CKD患者时,可参考广泛SGLT-2i准入可能带来的临床、经济与环境综合获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) affects >10% of the UK population and is expected to increase. Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are effective at slowing CKD progression; however, they are underprescribed because of barriers, including the need for urine albumin-creatinine ratio (UACR) testing and lack of guideline alignment. This study sought to quantify the clinical, economic, and environmental trade-offs of broad and restrictive SGLT-2i access in the UK. METHODS: Five scenarios exploring a range of SGLT-2i eligibility criteria for patients with CKD were modelled over 10 years, beginning from 2025, using the validated IMPACT CKD individual-level microsimulation model. SGLT-2i treatment was modelled to improve estimated glomerular filtration rate (eGFR) decline and reduce cardiovascular (CV) events and acute kidney injury. A 3.5%/yr discount was applied to economic outcomes. RESULTS: A maximally inclusive SGLT-2i scenario was compared with each of the less inclusive SGLT-2i eligibility criteria scenarios. Increasingly restrictive scenarios were projected to increase dialysis and all-cause mortality by 4.0% to 17.2% and 1.3% to 4.3%, respectively. Resulting from higher mortality, CKD prevalence was projected to decrease by 0.5% to 1.4%. Non-kidney replacement therapy (KRT) CKD costs and KRT costs were projected to increase by 0.7% to 2.1% and 2.4% to 10.6%, respectively, with increasingly restrictive scenarios. Total costs were projected to decrease by 15.2% to 33.9% because fewer patients are treated. Because of shifts to later stages, KRT-related environmental burden was projected to increase by 3.1% to 14.9%. CONCLUSION: Broad SGLT-2i eligibility criteria would likely reduce the holistic burden of CKD for patients, the National Health Service (NHS), and the environment.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tangri N, Priest S, Zara A, et al. Modelled CKD Benefits of Broad Sodium-Glucose Cotransporter-2 Inhibitor Eligibility in the UK. Kidney Int Rep. 2026. PMID: 42318531. doi:10.1016/j.ekir.2026.106602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。